Silibinin exerts cancer chemopreventive efficacy via targeting prostate cancer cell and cancer-associated fibroblast interaction
Prostate cancer (PCA) kills thousands in the US each year despite massive investment and success in improving early detection and treatment. Importantly, even successful treatment is still associated with persistent and often highly disruptive adverse health effects on the patient. As a consequence, the development of alternative treatment regimens like chemoprevention remains of great interest. Chemoprevention is intended for long-term and continuous use to prevent or halt disease even in individuals with no outward sign of disease. A developing tumor and its surrounding tumor microenvironment ...
(For more, see "View full record.")